Do we need coronavirus vaccination today?
https://doi.org/10.22625/2072-6732-2023-15-3-5-14
Abstract
The World Health Organization announced on May 4, 2023 that coronavirus infection is no longer a global emergency, but despite this, it proposed a strategy for 2023-2025 that includes the definition of immunization principles by each country, the need for case registrations and surveillance behind the virus. The review article presents data on high-risk groups for a severe course of a SARS-CoV-2 and new approaches to vaccination and revaccination recommended by WHO on depending on risk factors in patients and circulating new strains of the virus.
About the Authors
K. K. Tikhomirova
Pediatric Research and Clinical Center for Infectious Disease; Saint Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint Petersburg
Competing Interests:
None
S. M. Kharit
Pediatric Research and Clinical Center for Infectious Disease; Saint Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint Petersburg
Competing Interests:
None
References
1. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.05 May 2023. [Internet], Available from: https://www.who.int/ru/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet], Available from: https://covid19.who.int/
3. World Health Organization. (2023). COVID-19 weekly epidemiological update, Edition 153 published 27 July 2023. World Health Organization. [Internet], Available from: https://apps.who.int/iris/handle/10665/369373
4. Sravnenie pokazatelej infekcionnyh zabolevanij na internet resurse I-Monitoring, [Internet], dostupno: https://www.iminfin.ru/areas-of-analysis/health/perechen-zabolevanij?territory=40000000
5. Epidemiologicheskaya obstanovka i rasprostranenie COVID-19 v mire po sostoyaniyu na 8.00 po msk ot 23.07.2023 g po dannym FKUN RosNIPCHI «Mikrob» [Internet], dostupno https://www.rospotrebnadzor.ru/region/korono_virus/epid.php
6. О Sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2021 godu: Gosudarstvennyj doklad, 01.06.2022 [Internet], dostupno: https://www.rospotrebnadzor.ru/upload/iblock/594/sqywwl4tg5arqff6xvl5dss0l7vvuank/Gosudarstvennyy-doklad.-O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2021-godu.pdf
7. О Sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2022 godu: Gosudarstvennyj doklad, 01.06.2023 [Internet], dostupno: https://www.rospotrebnadzor.ru/bitrix/redirect.php?event1=file&event2=download&event3=GD-SEB.pdf&goto=/upload/iblock/b50/t4kqksh4b12a2iwjnha29922vu7naki5/GD-SEB.pdf
8. World Health Organization. WHO Health Emergency Dashboard. [Internet]. Available from: https://covid19.who.int/region/euro/country/ru
9. Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023 Jan;613(7942):130-137. doi: 10.1038/s41586-022-05522-2.
10. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020 Apr;92(4):441-447. doi: 10.1002/jmv.25689.
11. Shelkanov M.YU., Kolobuhina L.V., Burgasova O.A., i dr. COVID-19: etiologiya, klinika, lechenie // Infekciya i immunitet. – 2020. – T. 10. – №3. – C. 421-445. doi: 10.15789/2220-7619-CEC-1473.
12. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8.
13. R.C. Y. Woo, R. J. de Groot , B.Haagmans, S. K. P. Lau , B. W. Neuman , S. Perlman , I.Sola , Lia van der Hoek , A. C. P. Wong, Shiou-Hwei Yeh (2023):ICTV Virus Taxonomy Profile: Coronaviridae 2023, Journal of General Virology (in press) https://ictv.global/report/chapter/coronaviridae/coronaviridae
14. Hoffmann M., Kleine-Weber H., Krüger N., et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020 Jan;31.929042 doi: 10.1101/2020.01.31.929042.
15. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4.
16. World Health Organization. Tracking SARS-CoV-2 variants. [Internet], Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
17. Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5.
18. Karyakarte RP, Das R, Rajmane MV, Dudhate S, Agarasen J, et al. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India. Cureus. 2023 Jun 1;15(6):e39816. doi: 10.7759/cureus.39816. PMID: 37397651; PMCID: PMC10314318.
19. О.Cóbar, S. Cóbar. Omicron Variants World Prevalence, 150 WHO Weekly Epidemiological Update and CDC COVID Data Tracker Review, Preprint · July 2023 DOI: 10.13140/RG.2.2.27620.35209
20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
21. Hu FH, Jia YJ, Zhao DY, et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin Microbiol Infect. 2023 Jul;29(7):835-844. doi: 10.1016/j.cmi.2023.03.017.
22. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-882. doi: 10.1016/S2215-0366(20)30287-X.
23. Bystrickaya E. V., Bilichenko T. N. Zabolevaemost’, invalidnost’ i smertnost’ ot boleznej organov dyhaniya v Rossijskoj Federacii (2015–2019) //Pul’monologiya. – 2021. – T. 31. – №. 5. – S. 551-561.
24. S. L. Shein, .C.L. Carroll, .K. E. Remy, C. M. Rogerson, C. K. McCluskey, A. Lin, A.T. Rotta, Epidemiology and Outcome s of SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome in Children vs Influenza Among Critically Ill Children JAMA Network Open. 2022;5(6):e2217217. doi:10.1001/jamanetworkopen.2022.17217
25. Nguyen NN, Houhamdi L, Hoang VT, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.034.
26. Rodríguez-Grande C, Estévez A, Palomino-Cabrera R, et al. Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain. Emerg Infect Dis. 2023 Jun;29 (6):1154-1161. doi: 10.3201/eid2906.221696
27. R. Miyahara, K. Otani, T. Kamigaki, Y. Arima, M. Suzuki, K. Tamura, M. Nakazaki, H. Tani, K. Oishi, T. Kato, Y.K. Ko, SARS-CoV-2 Variants and Age-Dependent Infection Rates among Household and Nonhousehold Contacts Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 29, No. 8, August 2023, r.1648-50 DOI: https://doi.org/10.3201/eid2908.221582
28. Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Updated December 16, 2022. [Internet] Available from https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
29. Vremennye metodicheskie rekomendacii MZ RF «Medicinskaya reabilitaciya pri novoj koronavirusnoj infekcii (COVID-19)», versiya 3, 01.11.2022 [Internet] dostupno https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/202/original/%D0%92%D0%9A%D0%A0_%D0%9C%D0%A0_COVID_19__%D0%B2%D0%B5%D1%80%D1%81%D0%B8%D1%8F_07112022_%D0%B1%D0%B5%D0%B7_%D0%BF%D1%80%D0%B0%D0%B2%D0%BE%D0%BA.pdf?1669800267
30. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021 Aug 9;11(1):16144. doi: 10.1038/s41598-021-95565-8.
31. DeVries A, Shambhu S, Sloop S, Overhage JM. One-Year Adverse Outcomes Among US Adults With Post-COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database. JAMA Health Forum. 2023 Mar 3;4(3):e230010. doi: 10.1001/jamahealthforum.2023.0010.
32. Trapani G, Verlato G, Bertino E, et al. Long COVID-19 in children: an Italian cohort study. Ital J Pediatr. 2022 Jun 3;48(1):83. doi: 10.1186/s13052-022-01282-x.
33. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021 Mar;110(3):914-921. doi: 10.1111/apa.15673.
34. Osmanov IM, Spiridonova E, Bobkova P et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J. 2022 Feb 3;59(2):2101341. doi: 10.1183/13993003.01341-2021.
35. Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798. doi: 10.1016/S2213-8587(21)00244-8.
36. Muniangi-Muhitu H, Akalestou E, Salem V, et al. Covid-19 and Diabetes: A Complex Bidirectional Relationship. Front Endocrinol (Lausanne). 2020 Oct 8;11:582936. doi: 10.3389/fendo.2020.582936.
37. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr 6;377:e069590. doi: 10.1136/bmj-2021-069590.
38. Douillet D, Riou J, Penaloza A, et al. Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. Thromb Res. 2021 Dec;208:4-10. doi: 10.1016/j.thromres.2021.10.001.
39. J. DeCuir, D.Surie, Y. Zhu, et al Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19– Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network,19 U.S. States, February 1, 2022–January 31, 2023 MMWR / April 28, 2023 / Vol. 72 / No. 17,r 463-468.
40. Khunti K, Valabhji J, Misra S. Diabetes and the COVID-19 pandemic. Diabetologia. 2023 Feb;66(2):255-266. doi: 10.1007/s00125-022-05833-z.
41. Wong MK, Brooks DJ, Ikejezie J, et al. COVID-19 Mortality and Progress Toward Vaccinating Older Adults – World Health Organization, Worldwide, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):113-118. doi: 10.15585/mmwr.mm7205a1.
42. Riou M, Marcot C, Canuet M, et al. Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study. Respir Med Res. 2021 May;79:100801. doi: 10.1016/j.resmer.2020.100801.
43. Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. doi: 10.1111/dom.14124.
44. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020 Jun 20;395(10241):1919-1926. doi: 10.1016/S0140-6736(20)31173-9. Epub 2020 May 28. Erratum in: Lancet. 2020 Aug 22;396(10250):534.
45. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9.
46. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.
47. World Health Organization. WHO COVID-19 Vaccine Tracker and Landscape. [Internet]. Available from: https://covid19.trackvaccines.org/
48. Our world in data [Internet]. Available from: https://ourworldindata.org/covid-vaccinations
49. Rahmani K, Shavaleh R, Forouhi M, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front Public Health. 2022 Aug 26;10:873596. doi: 10.3389/fpubh.2022.873596.
50. Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022 May 23;20(1):200. doi: 10.1186/s12916-022-02397-y.
51. Balkan İİ, Dinc HO, Can G, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. Ir J Med Sci. 2023 Feb;192(1):19-25. doi: 10.1007/s11845-022-02984-1.
52. World Health Organization. (2023). COVID-19 weekly epidemiological update, edition 134, 16 March 2023. [Internet]. Available from: https://apps.who.int/iris/handle/10665/366534
53. Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022 Jul;54:100931. doi: 10.1016/j.blre.2022.100931.
54. Mattiuzzi C, Lippi G. Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly. Vaccines (Basel). 2023 Jan 18;11(2):213. doi: 10.3390/vaccines11020213.
55. Smits PD, Gratzl S, Simonov M, et al. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. doi: 10.1016/j.vaccine.2023.02.038.
56. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members – Chicago, Illinois, December 2020-March 2021. Am J Transplant. 2021 Jun;21(6):2290-2297. doi: 10.1111/ajt.16634.
57. Maltezou HC, Gamaletsou MN, Giannouchos TV, et al. Timing of last COVID-19 vaccine dose and SARS-CoV-2 break-through infections in fully (boosted) vaccinated healthcare personnel. J Hosp Infect. 2023 Feb;132:46-51. doi: 10.1016/j.jhin.2022.11.016.
58. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3.
59. Spinardi JR, Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines. 2023 Jan 27;11(2):370. doi: 10.3390/biomedicines11020370.
60. González S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021 Oct;40:101126. doi: 10.1016/j.eclinm.2021.101126.
61. Vokó Z, Kiss Z, Surján G, Surján O, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUNVE study. Clin Microbiol Infect. 2022 Mar;28(3):398-404. doi: 10.1016/j.cmi.2021.11.011.
62. Shkoda, A.S.; Gushchin, V.A.; Ogarkova, D.A.; Stavitskaya, S.V.; Orlova, O.E.; Kuznetsova, N.A.; Keruntu, E.N.; Pochtovyi, A.A.; Pukhov, A.V.; Kleymenov, D.A.; et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines 2022, 10, 938. https://doi.org/10.3390/vaccines10060938
63. Annex: Statement on the antigen composition of COVID-19 vaccines. 18 May 2023. [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/tag-co-vacannex-may-2023_final_18052023.pdf?sfvrsn=59fee9ec_2
64. World Health Organization. SAGE updates COVID-19 vaccination guidance. 28 March 2023. [Internet]. Available from: https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance
Review
For citations:
Tikhomirova K.K., Kharit S.M. Do we need coronavirus vaccination today? Journal Infectology. 2023;15(3):5-14. (In Russ.) https://doi.org/10.22625/2072-6732-2023-15-3-5-14
Views:
557
.png)
.png)
Email this article 